Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $245 from $260 and keeps an Equal Weight rating on the shares. The firm reduced estimates to reflect revised assumptions for life science growth in the second half of 2025 and 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
- Bio-Rad Laboratories Balances Growth and Challenges in Q1 2025 Earnings Call
- Bio-Rad price target lowered to $310 from $355 at UBS
- Bio-Rad price target lowered to $350 from $400 at Citi
- Bio-Rad Laboratories Reports Q1 2025 Financial Results
- Bio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5%